These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37847546)

  • 1. Subtle Structural Modification of a Synthetic Cannabinoid Receptor Agonist Drastically Increases its Efficacy at the CB1 Receptor.
    Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L
    ACS Chem Neurosci; 2023 Nov; 14(21):3928-3940. PubMed ID: 37847546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A subtle structural modification of a synthetic cannabinoid receptor agonist drastically increases its efficacy at the CB1 receptor.
    Yano H; Chitsazi R; Lucaj C; Tran P; Hoffman AF; Baumann MH; Lupica CR; Shi L
    bioRxiv; 2023 Jun; ():. PubMed ID: 37398099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo pharmacology of nine novel synthetic cannabinoid receptor agonists.
    Marusich JA; Gamage TF; Zhang Y; Akinfiresoye LR; Wiley JL
    Pharmacol Biochem Behav; 2022 Oct; 220():173467. PubMed ID: 36154844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and
    Cannaert A; Sparkes E; Pike E; Luo JL; Fang A; Kevin RC; Ellison R; Gerona R; Banister SD; Stove CP
    ACS Chem Neurosci; 2020 Dec; 11(24):4434-4446. PubMed ID: 33253529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Grafinger KE; Cannaert A; Ametovski A; Sparkes E; Cairns E; Banister SD; Auwärter V; Stove CP
    Drug Test Anal; 2021 Jul; 13(7):1402-1411. PubMed ID: 33769699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships for 5F-MDMB-PICA and its 5F-pentylindole analogs to induce cannabinoid-like effects in mice.
    Glatfelter GC; Partilla JS; Baumann MH
    Neuropsychopharmacology; 2022 Mar; 47(4):924-932. PubMed ID: 34802041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
    Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
    Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
    Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linking in vitro and ex vivo CB
    Janssens LK; Hudson S; Wood DM; Wolfe C; Dargan PI; Stove CP
    Arch Toxicol; 2022 Nov; 96(11):2935-2945. PubMed ID: 35962200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolites of Synthetic Cannabinoid 5F-MDMB-PINACA Retain Affinity, Act as High Efficacy Agonists and Exhibit Atypical Pharmacodynamic Properties at CB1 Receptors.
    Cabanlong CV; Russell LN; Fantegrossi WE; Prather PL
    Toxicol Sci; 2022 Apr; 187(1):175-185. PubMed ID: 35201352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB
    Patel M; Grimsey NL; Banister SD; Finlay DB; Glass M
    Pharmacol Res Perspect; 2023 Dec; 11(6):e01157. PubMed ID: 38018694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA.
    Ametovski A; Macdonald C; Manning JJ; Haneef SAS; Santiago M; Martin L; Sparkes E; Reckers A; Gerona RR; Connor M; Glass M; Banister SD
    ACS Chem Neurosci; 2020 Nov; 11(21):3672-3682. PubMed ID: 33054155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB
    Pike E; Grafinger KE; Cannaert A; Ametovski A; Luo JL; Sparkes E; Cairns EA; Ellison R; Gerona R; Stove CP; Auwärter V; Banister SD
    Drug Test Anal; 2021 Jul; 13(7):1383-1401. PubMed ID: 33787091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological evaluation of new generation OXIZID synthetic cannabinoid receptor agonists.
    Patel M; Zheng X; Akinfiresoye LR; Prioleau C; Walker TD; Glass M; Marusich JA
    Eur J Pharmacol; 2024 May; 971():176549. PubMed ID: 38561104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays.
    Grafinger KE; Vandeputte MM; Cannaert A; Ametovski A; Sparkes E; Cairns E; Juchli PO; Haschimi B; Pulver B; Banister SD; Stove CP; Auwärter V
    Drug Test Anal; 2021 Jul; 13(7):1412-1429. PubMed ID: 33908179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.
    Deventer MH; Van Uytfanghe K; Vinckier IMJ; Reniero F; Guillou C; Stove CP
    Drug Test Anal; 2022 Sep; 14(9):1565-1575. PubMed ID: 35560866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.
    Gamage TF; Farquhar CE; Lefever TW; Marusich JA; Kevin RC; McGregor IS; Wiley JL; Thomas BF
    J Pharmacol Exp Ther; 2018 May; 365(2):437-446. PubMed ID: 29549157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.